Payment overview · 2025
General Payments
$1,633.48
81 reported records · 18 companies
Healthcare provider profile · identity verified
Michael G Mercado, MD
Allopathic & Osteopathic Physicians|Family Medicine · WINTER GARDEN, FL · NPI 1558404616
Verified facts
What the public records show
CMS Open Payments records show Michael G Mercado, MD received $1,633.48 in general payments during 2025 across 81 reported records.
Novo Nordisk Inc accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $269.28 | 16.5% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $244.67 | 15.0% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $196.15 | 12.0% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $168.32 | 10.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.31 | 9.1% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $104.20 | 6.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $95.98 | 5.9% | 4 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $77.90 | 4.8% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.73 | 3.5% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $53.55 | 3.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $42.37 | 2.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.05 | 2.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.87 | 2.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.55 | 1.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.91 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.76 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.45 | 0.9% | 1 | 2025 |
| Hikma Pharmaceuticals USA | Unresolved — no canonical attribution shown | $14.43 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,633.48 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $244.67 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $242.14 | 12 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $196.15 | 17 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $146.35 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.93 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $104.20 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $102.96 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $95.98 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $94.71 | 8 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $77.90 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $57.73 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $53.55 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $42.37 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.05 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.05 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $31.55 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $28.82 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.82 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| Ryaltris Normalized: ryaltris |
Drug | Hikma Pharmaceuticals USA | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 141 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lidocaine | Lidocaine | 492 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 429 | 132 |
| Gabapentin | Gabapentin | 413 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 384 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 376 | 69 |
| Alprazolam | Alprazolam | 368 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 364 | 114 |
| Losartan Potassium | Losartan Potassium | 291 | 92 |
| Lisinopril | Lisinopril | 256 | 75 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 251 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 230 | 28 |
| Omeprazole | Omeprazole | 224 | 57 |
| Metformin Hcl | Metformin Hcl | 223 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 218 | 51 |
| Oxycodone Hcl | Oxycodone Hcl | 213 | 25 |
| Montelukast Sodium | Montelukast Sodium | 200 | 68 |
| Diclofenac Sodium | Diclofenac Sodium | 196 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 61 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 178 | 59 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 167 | 22 |
| Meloxicam | Meloxicam | 160 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 38 |
| Ketoconazole | Ketoconazole | 144 | 18 |
| Eliquis | Apixaban | 141 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 22 |
| Famotidine | Famotidine | 139 | 29 |
| Carvedilol | Carvedilol | 135 | 32 |
| Baclofen | Baclofen | 132 | 22 |
| Tramadol Hcl | Tramadol Hcl | 129 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 42 |
| Jardiance | Empagliflozin | 124 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 38 |
| Simvastatin | Simvastatin | 110 | 30 |
| Trazodone Hcl | Trazodone Hcl | 103 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 29 |
| Allopurinol | Allopurinol | 99 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 29 |
| Azithromycin | Azithromycin | 96 | 68 |
| Furosemide | Furosemide | 96 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 89 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 23 |
| Ozempic | Semaglutide | 89 | 24 |
| Sertraline Hcl | Sertraline Hcl | 87 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 77 | 24 |
| Ibuprofen | Ibuprofen | 77 | 22 |
| Mupirocin | Mupirocin | 74 | 19 |
| Pregabalin | Pregabalin | 74 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 18 |
| Promethazine Hcl | Promethazine Hcl | 70 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 39 |
| Methocarbamol | Methocarbamol | 60 | 15 |
| Temazepam | Temazepam | 60 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 12 |
| Januvia | Sitagliptin Phosphate | 54 | 13 |
| Nitroglycerin | Nitroglycerin | 53 | 13 |
| Potassium Chloride | Potassium Chloride | 53 | 13 |
| Trulicity | Dulaglutide | 53 | 11 |
| Ezetimibe | Ezetimibe | 52 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 11 |
| Naproxen | Naproxen | 49 | 13 |
| Synthroid | Levothyroxine Sodium | 49 | suppressed |
| Vascepa | Icosapent Ethyl | 48 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 12 |
| Spironolactone | Spironolactone | 47 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 16 |
| Ondansetron Odt | Ondansetron | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 31 |
| Clonidine Hcl | Clonidine Hcl | 41 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 11 |
| Diazepam | Diazepam | 38 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 38 | 11 |
| Sucralfate | Sucralfate | 38 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 13 |
| Alendronate Sodium | Alendronate Sodium | 33 | 12 |
| Linzess | Linaclotide | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 11 |
| Mounjaro | Tirzepatide | 32 | 11 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Prednisone | Prednisone | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 14 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 20 |
| Varenicline Tartrate | Varenicline Tartrate | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Calcipotriene | Calcipotriene | 13 | suppressed |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,633.48 · 81 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, CREON, ELIQUIS, FARXIGA, INTELLIS ADAPTIVESTIM, JARDIANCE, Kerendia, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Ryaltris, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, Xhance, ZENPEP | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error